| AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies SD Zabludoff, C Deng, MR Grondine, AM Sheehy, S Ashwell, BL Caleb, ... Molecular cancer therapeutics 7 (9), 2955-2966, 2008 | 445 | 2008 |
| Treatment and prevention of urinary tract infection with orally active FimH inhibitors CK Cusumano, JS Pinkner, Z Han, SE Greene, BA Ford, JR Crowley, ... Science translational medicine 3 (109), 109ra115-109ra115, 2011 | 347 | 2011 |
| Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics CX Ma, JW Janetka, H Piwnica-Worms Trends in molecular medicine 17 (2), 88-96, 2011 | 305 | 2011 |
| Structure-based drug design and optimization of mannoside bacterial FimH antagonists Z Han, JS Pinkner, B Ford, R Obermann, W Nolan, SA Wildman, D Hobbs, ... Journal of medicinal chemistry 53 (12), 4779-4792, 2010 | 297 | 2010 |
| Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist CN Spaulding, RD Klein, S Ruer, AL Kau, HL Schreiber, ZT Cusumano, ... Nature 546 (7659), 528-532, 2017 | 267 | 2017 |
| MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A AG Rocha, A Franco, AM Krezel, JM Rumsey, JM Alberti, WC Knight, ... Science 360 (6386), 336-341, 2018 | 231 | 2018 |
| Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control AM Aronov, Q Tang, G Martinez-Botella, GW Bemis, J Cao, G Chen, ... Journal of medicinal chemistry 52 (20), 6362-6368, 2009 | 185 | 2009 |
| Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides Z Han, JS Pinkner, B Ford, E Chorell, JM Crowley, CK Cusumano, ... Journal of medicinal chemistry 55 (8), 3945-3959, 2012 | 156 | 2012 |
| Dynamic combinatorial chemistry: in drug discovery, bioorganic chemistry, and materials science BL Miller John Wiley & Sons, 2009 | 155 | 2009 |
| A FimH Inhibitor Prevents Acute Bladder Infection and Treats Chronic Cystitis Caused by Multidrug-Resistant Uropathogenic Escherichia coli ST131 M Totsika, M Kostakioti, TJ Hannan, M Upton, SA Beatson, JW Janetka, ... The Journal of infectious diseases 208 (6), 921-928, 2013 | 151 | 2013 |
| Pyrazole compositions useful as inhibitors of ERK M Hale, J Janetka, F Maltais, J Cao US Patent 6,784,195, 2004 | 138 | 2004 |
| Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors AM Aronov, C Baker, GW Bemis, J Cao, G Chen, PJ Ford, UA Germann, ... Journal of medicinal chemistry 50 (6), 1280-1287, 2007 | 137 | 2007 |
| Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice PS Guiton, CK Cusumano, KA Kline, KW Dodson, Z Han, JW Janetka, ... Antimicrobial agents and chemotherapy 56 (9), 4738-4745, 2012 | 129 | 2012 |
| Pyrazole compositions useful as inhibitors of ERK M Hale, X Xie, J Green, J Cao, C Baker, F Maltais, J Janetka, G Bemis, ... US Patent 6,528,509, 2003 | 124 | 2003 |
| Pyrazole compositions useful as inhibitors of ERK M Hale, X Xie, J Green, J Cao, C Baker, F Maltais, J Janetka, G Bemis, ... US Patent 6,528,509, 2003 | 124 | 2003 |
| Pyrazole compositions useful as inhibitors of ERK M Hale, X Xie, J Green, J Cao, C Baker, F Maltais, J Janetka, G Bemis, ... US Patent 6,528,509, 2003 | 124 | 2003 |
| Pyrazole compositions useful as inhibitors of ERK M Hale, X Xie, J Green, J Cao, C Baker, F Maltais, J Janetka, G Bemis, ... US Patent 6,528,509, 2003 | 124 | 2003 |
| Pyrazole compositions useful as inhibitors of ERK M Hale, X Xie, J Green, J Cao, C Baker, F Maltais, J Janetka, G Bemis, ... US Patent 6,528,509, 2003 | 124 | 2003 |
| Hepatocyte growth factor, a key tumor-promoting factor in the tumor microenvironment BY Owusu, R Galemmo, J Janetka, L Klampfer Cancers 9 (4), 35, 2017 | 118 | 2017 |
| Total synthesis of the cyclic biphenyl ether peptides K-13 and OF4949-III via SNAr macrocyclization of peptidyl ruthenium π-arene complexes JW Janetka, DH Rich Journal of the American Chemical Society 119 (28), 6488-6495, 1997 | 116 | 1997 |
Laurel Mydock-McGraneFimbrion TherapeuticsVerified email at fimbrion.com
